 |
|
Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis
Kyung Hoon Kim, Byoung Kuk Jang, Woo Jin Chung, Jae Seok Hwang, Young Oh Kweon, Won Young Tak, Heon Ju Lee, Chang Hyeong Lee, Jeong Ill Suh
Korean J Hepatol. 2011;17(3):220-225. Published online 2011 Sep 30 DOI: https://doi.org/10.3350/kjhep.2011.17.3.220
|
|
Citations to this article as recorded by
 Cost‐effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea
Wankyo Chung, Kyung‐Ah Kim, Eun Sun Jang, Moran Ki, Hwa Young Choi, Sook‐Hyang Jeong
Journal of Gastroenterology and Hepatology.2019; 34(4): 776. CrossRef Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection
Mashael R. Al-Anazi, Sabine Matou-Nasri, Ayman A. Abdo, Faisal M. Sanai, Saad Alkahtani, Saud Alarifi, Abdullah A. Alkahtane, Hamad Al-Yahya, Daoud Ali, Mohammed S. Alessia, Bushra Alshahrani, Mohammed N. Al-Ahdal, Ahmed A. Al-Qahtani
Journal of Immunology Research.2017; 2017: 1. CrossRef Urgency to treat patients with chronic hepatitis C in Asia
Jia-Horng Kao, Sang Hoon Ahn, Rong-Nan Chien, Mong Cho, Wan-Long Chuang, Sook-Hyang Jeong, Chen-Hua Liu, Seung-Woon Paik
Journal of Gastroenterology and Hepatology.2017; 32(5): 966. CrossRef The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia
Snezana Jovanovic-Cupic, Sanja Glisic, Maja Stanojevic, Darko Nozic, Nina Petrovic, Vesna Mandusic, Milena Krajnovic
Archives of Virology.2016; 161(5): 1189. CrossRef Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
Chang Ho Jung, Soon Ho Um, Tae Hyung Kim, Sun Young Yim, Sang Jun Suh, Hyung Joon Yim, Yeon Seok Seo, Hyuk Soon Choi, Hoon Jai Chun
Gut and Liver.2016; 10(5): 808. CrossRef All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study
Jia-Horng Kao, Youn-Jae Lee, Jeong Heo, Sang-Hoon Ahn, Young-Suk Lim, Cheng-Yuan Peng, Ting-Tsung Chang, Anne Torbeyns, Eric Hughes, Rafia Bhore, Stephanie Noviello
Liver International.2016; 36(10): 1433. CrossRef Treatment of Hepatitis C in Special Conditions: Liver Cirrhosis
Geum-Youn Gwak
Korean Journal of Medicine.2015; 88(6): 643. CrossRef Management of HCV in Cirrhosis—a Rapidly Evolving Landscape
Suraj A. Sharma, Jordan J. Feld
Current Gastroenterology Reports.2015;[Epub] CrossRef KASL clinical practice guidelines: Management of Hepatitis C
Clinical and Molecular Hepatology.2014; 20(2): 89. CrossRef Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients
Hyun Seok Lee, Young Oh Kweon, Won Young Tak, Soo Young Park, Eun Jung Kang, Yu Lim Lee, Hae Min Yang, Hyun Woo Park
Clinical and Molecular Hepatology.2013; 19(2): 148. CrossRef Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review
Simona Bota
World Journal of Hepatology.2013; 5(3): 120. CrossRef
|